1. Research and Innovation Research and Innovation Promoting health research and innovation in Horizon 2020 Research and Innovation Research and Innovation Jeremy Bray Policy Advisor Health Directorate Directorate-General for Research and Innovation European Commission Alliance for Biomedical Research in Europe 16 November 2012

2. Research and Innovation Summary messages  Horizon 2020  We know the health 'what'  We know some of the 'how'  We don't know the 'how much'…  What about governance?

3. Research and Innovation If it isn't broken? Aggregated data 2002-10 1,210 projects funded 4.9 billion euros invested 14,000 teams 114 countries ~50% of projects on-going 70,000 PubMed publications 50,000 high-skilled jobs 23.3% listed on patent application(s) 17% envisage creating a SME 7.4% created one or more SMEs

4. Policy Research and Innovation Research and Innovation The necessity to invest in R&D

5. Research and Innovation EU v US – fragmentation and underinvestment Towards joint programming in research Working together to tackle common challenges more effectively, EU COM (2008) 468 Dementia Alzheimer Brain disease Cancer Low coordination/ high fragmentation, invest less than the US Medium coordination/ fragmentation, invest less than the US

6. Research and Innovation Research and Innovation H2020 - €80bn for… 1.Excellent science i.ERC, FET, Marie Curie, infrastructures 2.Industrial leadership i.LEIT, risk finance, SME 3.Societal challenges i.Health, Food, Energy, Transport, Climate, Security

7. Research and Innovation In the pipeline:  IMI2  EDCTP2  SME / SBIR  International consortia  Clinical research  Roll-out  Common characteristics?

8. Research and Innovation 10 regulators 17 patient org 92 SMEs 508 academic & research teams 341 EFPIA teams 603 million EUR IMI JU cash contribution 600 million EUR EFPIA in kind contribution ~ 3500 researchers > 200 publications EU-AIMS contribution to autism eTOX contribution to cardiotoxicity IMI Key Figures of the 37 Projects to date

9. Research and Innovation Strategic Business Plan to ensure critical level of commitment to EDCTP2 Plans to keep scope and mandate Proposal for EU legislation on EDCTP2 co-funding under development High-Level Conference in Cape Town, 5 Nov 2012 Current Partnership Renewal of the "European and Developing Countries Clinical Trials Partnership"

10. Research and Innovation International Rare Diseases Research Consortium (IRDiRC) 200 new therapies and means to diagnose most rare diseases by the year 2020 © Yuri Arcurs/Fotolia.com © nyul/Fotolia.com

11. Research and Innovation Europe European Commission (EU) EURORDIS (EU) French Association against Myopathies (FR) French National Research Agency (FR) German Federal Ministry of Education and research (DE) Italian Higher Institute of Health Research (IT) Italian Telethon Foundation (IT) Lysogene (FR) Netherlands Organisation for Health Research and Development Prosensa (NL) Shire (IE) Spanish Carlos III Health Institute (ES) UK National Institute for Health Research (UK) 28 committed members North America Canadian Institutes for Health Research (CA) FDA Orphan Products Grants Program (US) Genome Canada (CA) Genetic Alliance (US) Mendelian Disorders Genome Centres (US) National Centre for Translational Therapeutics (US) National Cancer Institute (US) National Institute of Neurological Disorders and Stroke (US) National Institute of Arthritis and Musculoskeletal and Skin Diseases (US) National Institute of Child Health and Human Development (US) National Eye Institute (US) NORD (US) Office of Rare Diseases (US) Sanford Research (US) © rtguest/Fotolia.com Australia Western Australian Department of Health

12. Research and Innovation International Mouse Consortium International Cancer Genomics Consortium IRDiRC: one of several international collaborations International Human Metagenome Consortium International Human Epigenome Consortium International Rare Diseases Research Consortium International Initiative for Traumatic Brain Injury Research © rtguest/Fotolia.com

13. Research and Innovation Conclusions  One size does not fit all  Broader participation brings benefit – is dependent on trust and instrument suited to challenge  This takes time  Governance must also be reflective of this variety

14. Research and Innovation

15. a long term endeavour…

16. Research and Innovation Horizon 2020 timeline  From 30/11 Parliament and Council negotiations on the basis of the Commission proposals  On-going Parliament and Council negotiations on EU budget 2014-20 (including Horizon 2020)  By end 2013 Adoption of legislative acts by Parliament and Council on Horizon 2020  January 2014 Horizon 2020 starts; launch of first calls 2011 2012 2013 2014